Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 147Breast Neoplasms 108Lung Neoplasms 93Carcinoma, Non-Small-Cell Lung 78Neoplasm Metastasis 68Glioblastoma 68Brain Neoplasms 65Glioma 59Pancreatic Neoplasms 46Carcinoma, Renal Cell 43Multiple Myeloma 41Squamous Cell Carcinoma of Head and Neck 39Colorectal Neoplasms 39Lymphoma, Large B-Cell, Diffuse 37Neoplasms 34Melanoma 33Lymphoma 32Carcinoma, Hepatocellular 32Urinary Bladder Neoplasms 31Ovarian Neoplasms 29Astrocytoma 28Sarcoma 25Oropharyngeal Neoplasms 24Lymphoma, Follicular 23Central Nervous System Neoplasms 23Rectal Neoplasms 22Uterine Cervical Neoplasms 21Triple Negative Breast Neoplasms 21Mouth Neoplasms 21Lymphoma, Non-Hodgkin 21

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Specimen Handling 3Paclitaxel 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Carboplatin 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Sunitinib 2Standard of Care 2Riluzole 2Radiation Dose Hypofractionation 2Prednisone 2Pluvicto 2Mitomycin 2LDP-02 2Infliximab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Urogenital Neoplasms × Magnetic Resonance Spectroscopy × Clear all
NCT03866382 2026-06-03

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

National Cancer Institute (NCI)

Phase 2 Recruiting
314 enrolled
Genitourinary

Urachal adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Penile Neoplasms, Prostatic Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

NCT00147238 2012-08-07

A Validation Study of MR Lymphangiography Using SPIO, a New Lymphotropic Superparamagnetic Nanoparticle Contrast

M.D. Anderson Cancer Center

Phase NA Terminated
10 enrolled 3 charts
Genitourinary

Urinary Bladder Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡